Kyle Lefkoff is Director at ARRAY BIOPHARMA INC (ARRY). They have made 18 open-market trades across 3 companies since 2006, most recently 2019-07-30.
CIK 0001191818
4 open-market purchases totalling $63K since 2008, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARRY | SELL | 2019-02-06 | 2019-02-08 | $20.56 | $1.2M | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2018-07-06 | 2018-07-06 | $17.45 | $873K | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2018-02-09 | 2018-02-12 | $17.01 | $1.7M | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2017-09-29 | 2017-09-29 | $12.31 | $957K | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2017-03-31 | 2017-04-04 | $8.92 | $401K | +33.9% | +23.6% | +23.6% |
| MGEN | SELL | 2017-03-09 | 2017-03-13 | $14.34 | $83K | -16.7% | -3.2% | -33.0% |
| MGEN | SELL | 2017-03-06 | 2017-03-08 | $15.52 | $378K | -17.3% | -16.1% | -36.9% |
| MGEN | SELL | 2017-02-24 | 2017-02-28 | $13.89 | $143K | +3.7% | -10.8% | -22.9% |
| MGEN | SELL | 2017-02-22 | 2017-02-24 | $14.23 | $142K | -1.5% | -12.7% | -25.5% |
| ARRY | SELL | 2015-03-03 | 2015-03-04 | $8.00 | $560K | +33.9% | +23.6% | +23.6% |
| RALY | SELL | 2013-07-10 | 2013-07-12 | $24.81 | $49K | N/A | N/A | N/A |
| ARRY | BUY | 2011-08-11 | 2011-08-11 | $2.22 | $11K | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2010-11-16 | 2010-11-18 | $3.27 | $33K | +33.9% | +23.6% | +23.6% |
| ARRY | BUY | 2010-05-07 | 2010-05-11 | $3.71 | $15K | +33.9% | +23.6% | +23.6% |
| ARRY | BUY | 2008-11-13 | 2008-11-13 | $3.28 | $10K | +33.9% | +23.6% | +23.6% |
| ARRY | BUY | 2008-03-10 | 2008-03-12 | $5.39 | $27K | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2006-11-09 | 2006-11-09 | $11.70 | $597K | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2006-02-21 | 2006-02-22 | $9.02 | $99K | +33.9% | +23.6% | +23.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.